Anti-thymocyte globulin (ATG)

DRUG13 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Stanford University, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Autoimmune DiseasesB-cell LymphomaBlood CancerChediak-Higashi SyndromeChronic Lymphocytic LeukemiaChronic Myelomonocytic Leukemia

Phase 1

Infusion of Expanded Cord Blood T Cells

WithdrawnNCT00972101

M.D. Anderson Cancer CenterLeukemia, Lymphoma, Pediatric Disorders +1

Start: 2009-09-30End: 2011-09-30Updated: 2012-10-11

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

CompletedNCT01758328

Memorial Sloan Kettering Cancer CenterMultiple Myeloma

Start: 2012-12-31End: 2025-03-17Updated: 2025-03-20

Diabetes Islet Preservation Immune Treatment

WithdrawnNCT02586831

Camillo Ricordi and Jay SkylerAutoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1 +1

Start: 2024-06-01End: 2024-06-01Updated: 2026-01-15

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

RecruitingNCT07061574

City of Hope Medical CenterNew Onset, Type 1 Diabetes

Start: 2026-03-30End: 2031-04-15Target: 120Updated: 2026-03-16

Phase 2

Stem Cell Transplant for Immunologic or Histiocytic Disorders

CompletedNCT00176865

Masonic Cancer Center, University of MinnesotaChediak-Higashi Syndrome, Griscelli Syndrome, Hemophagocytic Lymphohistiocytosis +3

Start: 2002-08-31End: 2014-08-31Updated: 2017-12-28

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

CompletedNCT00185640

Stanford UniversityBlood Cancer, Leukemia

Start: 2003-03-31End: 2016-01-31Updated: 2021-06-29

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

TerminatedNCT00482053

Stanford UniversityDiffuse Large B-cell Lymphoma (DLBCL), Lymphoma, B-cell, Lymphoma, Non-Hodgkin +1

Start: 2006-10-31End: 2010-05-31Updated: 2018-05-14

ATG-GCSF in New Onset Type 1 Diabetes

CompletedNCT02215200

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Diabetes Mellitus, Type 1

Start: 2014-12-31End: 2018-08-31Updated: 2020-03-02

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

CompletedNCT03734601

Stanford UniversityAcute Myeloid Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia +6

Start: 2018-11-05End: 2020-11-17Updated: 2023-12-12

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

TerminatedNCT05579769

St. Jude Children's Research HospitalHematologic Malignancy, Myeloid Malignancy

Start: 2023-03-14End: 2024-05-08Updated: 2025-10-02

Advancing Transplantation Outcomes in Children

RecruitingNCT06055608

National Institute of Allergy and Infectious Diseases (NIAID)Kidney Transplant

Start: 2024-05-22End: 2028-06-30Target: 200Updated: 2026-03-02

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

RecruitingNCT06455319

University of FloridaType 1 Diabetes

Start: 2025-11-12End: 2030-08-31Target: 60Updated: 2025-11-26

Phase 3

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

TerminatedNCT00568633

Stanford UniversityAcute Myeloid Leukemia (AML), Leukemia, Leukemia, Myeloid

Start: 2007-08-31End: 2015-12-31Updated: 2019-09-24

Related Papers

Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation.

2024-12-204 citations

Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes

JCI Insight2023-07-1130 citations

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

2016-04-0668 citations

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

2009-05-07125 citations